Nanoviricides Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nanoviricides Inc 's ROA in the third quarter of 2026?
Nanoviricides Inc recorded a cumulative net loss of $-8 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -89.34%.

However, within the Healthcare sector 713 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4215, from total ROA ranking in the second quarter of 2026 at 4921.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter
Y / Y Total Assets Change	1.86 %	-31.18 %	-28.82 %	-31.18 %	-12.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-8	-8	-9	-10
Return On Assets (TTM)	-89.34 %	-92.33 %	-81.18 %	-87.21 %	-82.05 %
NNVC's Total Ranking	# 4215	# 4921	# 4303	# 4384	# 4425
Total Assets (TTM) in million	10	9	8	9	10
Seq. Total Assets Change	15.81 %	5.59 %	-5.29 %	-12.04 %	-21.77 %
Seq. Net Income Change	-	-	-	-	-

NNVC's 5 Years Annual ROA >> Back to NNVC Management Effectiveness >> Compare NNVC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 327
Sector	# 714
Overall	# 4177

Return On Assets Statistics
High	Average	Low
-4.79 %	-45.96 %	-99.86 %
(Jun 30 2015)		(Mar 31 2020)

Financial Statements
Nanoviricides Inc 's Assets	$ 10 million	NNVC's Balance sheet
Nanoviricides Inc 's Income	$ -2 million	Quarterly NNVC's Income Statement
NNVC's Income by Division		See NNVC's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	-31.18 %	-24.12 %	-28.07 %	-22.36 %	26.54 %
Total Assets in million	9	13	17	23	30
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-9	-8	-9	-8	-9
Annual Return On Assets	-107.29 %	-64.68 %	-50.82 %	-34.5 %	-29.15 %

NNVC's 5 Years Annual ROA >> Back to NNVC Management Effectiveness >> Compare NNVC ROA to its Competitors

More Return On Assets Ratios
NNVC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NNVC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NNVC's Competitors
Subscribers only: Roa for Nanoviricides Inc 's Suppliers
Subscribers only: Return On Assets for NNVC's Customers

You may also want to know
NNVC's Roi	NNVC's Inventory Turnover Ratio	NNVC's Growth Rates	NNVC's Dividend Comparisons
	NNVC's Profitability Ratios	NNVC's Asset Turnover Ratio	NNVC's Dividend Growth
NNVC's Roe	NNVC's Valuation Ratios	NNVC's Financial Strength Ratios	NNVC's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T10:33:11+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.